Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab in Combination With Ruxolitinib in Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of axatilimab in chronic graft-versus-host disease (cGVHD), sponsored by Incyte. Started Oct 2024; status: active, not recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06388564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388564.